Two articles report results from the Phase 3 BE OPTIMAL and BE COMPLETE studies evaluating bimekizumab, a selective inhibitor of IL-17A and IL-17F, in patients with psoriatic arthritisBrussels (Belgium), 7th December 2022 – 07:00 (CET) – UCB, a global biopharmaceutical company, today announced that .
Late-breaking 52-week data on investigational bimekizumab in the treatment of adults with active psoriatic arthritis and active axial spondyloarthritis to be presentedNew data on CIMZIA® (certolizumab pegol) and bimekizumab underscore UCB’s commitment to innovative research in rheumatology Brussels (B.
/PRNewswire/ UCB, a global biopharmaceutical company, today announced that it will present 15 abstracts across its rheumatology portfolio at ACR Convergence.
/PRNewswire/ UCB, a global biopharmaceutical company, today announced that it will present 15 abstracts across its rheumatology portfolio at ACR Convergence.
UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.